It trades at 13.3 times forward earnings—below the industry average of 14, as measured by the NYSE Arca Pharmaceutical Index, ...

Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...

The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

People living with HIV have a significantly increased risk of cardiovascular disease that requires a different level of ...

The drug, Lenacapavir, has shown exceptional promise in clinical trials, including research conducted in Houston. In Harris County, new HIV cases are diagnosed at a significantly higher rate than ...

By bolstering immune cells, researchers at ViiV Healthcare in Branford have designed long-acting drugs that prevent infection ...

The current administration has pulled millions in HIV-related grants and cut staffing positions essential to research and ...

(Reuters) -Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in ...

A UVa researcher has discovered that NRTIs, drugs used to treat HIV, can also help prevent Alzheimer's and a long list of ...

The lack of funding is expected to set back decades' worth of progress against HIV, according to public health experts.